New drug INCA036873 enters human trials for Hard-to-Treat cancers

NCT ID NCT07195916

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug through an IV, and researchers will monitor side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INCA036873 (an experimental drug given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors and certain blood cancers that have not responded to prior therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects. Only a small number of participants will receive the optimal dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma diffuse large B-cell lymphoma hematopoietic and lymphoid system neoplasm high grade B-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides non-Hodgkin lymphoma nonpapillary renal cell carcinoma primary cutaneous T-cell non-Hodgkin lymphoma renal cell carcinoma Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Aarhus University Hospital
NOT_YET_RECRUITING

Aarhus, 08200, Denmark
Aou Policlinico S. Orsola-Malpighi
NOT_YET_RECRUITING

Bologna, 40138, Italy
Cancer Research Sa
RECRUITING

Adelaide, South Australia, 05000, Australia
Centro Ricerche Cliniche Di Verona
NOT_YET_RECRUITING

Verona, 37134, Italy
City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
Cliniques Universitaires Ucl Saint-Luc
NOT_YET_RECRUITING

Brussels, 01200, Belgium
Fondazione Irccs Istituto Nazionale Dei Tumori
NOT_YET_RECRUITING

Milan, 20133, Italy
Macquarie University Hospital
RECRUITING

Sydney, New South Wales, 02109, Australia
Md Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10021, United States
Peter Maccallum Cancer Centre-Royal Melbourne Hospital
RECRUITING

Melbourne, Victoria, 03000, Australia
Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
NOT_YET_RECRUITING

Rome, 00168, Italy
Princess Alexandra Hospital Australia
RECRUITING

Woolloongabba, Queensland, 04102, Australia
Rigshospitalet Uni of Hospital of Copenhagen
NOT_YET_RECRUITING

Copenhagen, DK-2100, Denmark
Scri Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
The University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States
Universitair Ziekenhuis Antwerpen
NOT_YET_RECRUITING

Edegem, 02650, Belgium
Universitair Ziekenhuis Gent (Uz Gent)
NOT_YET_RECRUITING

Ghent, 09000, Belgium
Universitair Ziekenhuis Leuven
RECRUITING

Leuven, 03000, Belgium
University of California San Diego Medical Center, Moores Cancer Center
NOT_YET_RECRUITING

La Jolla, California, 92037, United States
University of Michigan
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States
Vanderbilt Medical Center
NOT_YET_RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.